Company shares last traded at $100.55 just a bit higher than $92.40, the 50 day moving average and a great deal higher than the 200 day moving average of $87.22. The 50 day moving average was up by +8.83% whereas the 200 day moving average was up $13.33 or +15.28%. 165K shares changed hands in the last trading session. Trading volume was up 32.45% over the stocks average daily volume.
Investors are a little more bearish on shares of Penumbra, Inc. lately if you take a look at the motion in short interest. The firm experienced a rise in short interest of 0.92% as of October 13, 2017 from the last reporting period. Short interest increased 25,228 over that timeframe. Days to cover increased 6.0 to 26.0 and the percentage of shorted shares was 0.08% on October 13.
Here is a rundown on some insider market activity for Penumbra, Inc. (NYSE:PEN). Robert D. Evans, EVP disclosed the sale of 4,983 shares. The shares were sold on September 21st for a price of $90.00. The EVP now owns $20,368,170 of the stock according to the SEC filing. EVP Robert D. Evans disclosed the sale of 20,017 shares of (PEN). The shares sold for $90.01. Evans now owns $18,568,703 of the stock per the Form 4 SEC filing.
The following firms have recently changed their position in PEN. Strs Ohio grew its position by buying 13,600 shares an increase of 647.6%. Strs Ohio owns 15,700 shares with a value of $1,417,000. The total value of its holdings increased 670.1%. Cable Hill Partners, LLC reduced its investment by shedding 3 shares a decrease of 2.3% as of 09/30/2017. Cable Hill Partners, LLC now controls 130 shares worth $12,000. The value of the position overall is down by 0.0%.
As of quarter end First Trust Advisors Lp had bought a total of 26,215 shares growing its holdings by 118.6%. The value of the company’s investment in Penumbra, Inc. increased from $1,940,000 to $4,364,000 a change of $2,424,000 quarter to quarter. As of the end of the quarter Nationwide Fund Advisors had acquired 2,841 shares growing its position 3.1%. The value in dollars went from $8,008,000 to $8,497,000 a change of 6.1% quarter over quarter.
The company’s P/E ratio is 679.39 and market capitalization is 3.40B. As of the last earnings report the EPS was $0.15 and is estimated to be $-0.21 for the current year with 33,772,000 shares presently outstanding. Next quarter’s EPS is expected be $-0.02 with next year’s EPS projected to be $0.10.
Penumbra, Inc., launched on June 21, 2004, is a healthcare company focused on interventional therapies. The Company designs, develops, manufactures and markets medical devices. The Company has a portfolio of products that addresses medical conditions and clinical needs across two markets, neuro and peripheral vascular. The conditions that its products address include ischemic stroke, hemorrhagic stroke and various peripheral vascular conditions that can be treated through thrombectomy and embolization procedures. The Company focuses on developing, manufacturing and marketing products for use by specialist physicians, including interventional neuroradiologists, neurosurgeons, interventional neurologists, interventional radiologists and vascular surgeons..